Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-carnitine for nonalcoholic fatty liver disease
IRCT20240129060837N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of levocarnitine in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Ahvaz Jundishapur University of Medical Sciences. Started Mar 2024; status: completed.
02
Drugs
levocarnitine
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20240129060837N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240129060837N1.